NCT03364049View on ClinicalTrials.gov

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

October 19, 2020

Study Completion Date

October 19, 2020

Conditions
Solid Neoplasms
Interventions
DRUG

MK-7162

oral tablets

BIOLOGICAL

Pembrolizumab

IV infusion

Trial Locations (6)

10016

Laura and Isaac Perlmutter Cancer Center ( Site 0001), New York

49546

START Midwest ( Site 0007), Grand Rapids

90404

UCLA Medical Center ( Site 0002), Santa Monica

5265601

Chaim Sheba Medical Center. ( Site 0301), Ramat Gan

M5G 2M9

Princess Margaret Hospital.. ( Site 0130), Toronto

03722

Severance Hospital Yonsei University Health System ( Site 0103), Seoul

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03364049 - Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | Biotech Hunter | Biotech Hunter